Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Read More

Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

Read More

Ryvu Therapeutics to Participate in Upcoming Investor Conferences

Read More

Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).

Read More

Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Read More

Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting

Read More

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Read More

Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

Read More